Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID07324070

Electroconvulsive Therapy Augmented with Transcranial Magnetic Stimulation for Treatment-Resistant Depression

Led by Charles University, Czech Republic · Updated on 2026-01-07

50

Participants Needed

1

Research Sites

52 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the use of electroconvulsive therapy (ECT) combined with transcranial magnetic stimulation (TMS) to treat people with major depressive disorder who have not responded to other treatments. This study is randomized, sham-controlled, and triple-blind, aiming to see if TMS priming before ECT can reduce the seizure threshold needed for ECT. The study focuses on measuring the overall applied energy dose and recovery times after treatment. Participants are randomly assigned to one of two groups, receiving either active TMS with ECT or sham TMS with ECT. TMS is given using the intermittent theta burst stimulation (iTBS) protocol targeting the left dorsolateral prefrontal cortex shortly before ECT, ideally within two minutes. ECT doses are set based on seizure threshold and adjusted if seizures are insufficient. The treatments use specific devices: the MECTA SIGMA for ECT and the Deymed DuoMAG XT for TMS/iTBS. During the study, participants are closely monitored with psychometric scales including MADRS, cognitive assessments, and memory tests at baseline, during treatment, and after the ECT course. Recovery time after each ECT session is measured in minutes. The study includes careful safety monitoring throughout the treatment period. The total duration of participation aligns with the ECT course and assessment schedule, ending within days after the final treatment.

CONDITIONS

Brief Title

Electroconvulsive Therapy Augmented With Transcranial Magnetic Stimulation for Treatment Resistant Depression

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age equal to 18 or higher
  • Montgomery-Asberg Depression Scale (MADRS) score of 20 or higher
  • Diagnosis of major depressive disorder according to ICD 10
Not Eligible

You will not qualify if you...

  • Other axis 1 disorders such as schizophrenia or addiction
  • Dementia
  • Electroconvulsive therapy (ECT) in the last 3 months
  • Transcranial magnetic stimulation (TMS) in the last 3 months
  • Psychotic disease or symptoms
  • Pregnancy or lactation
  • Any neurological disease, including epilepsy
  • Participation in another clinical trial within the last 30 days
  • Somatic conditions that contraindicate ECT

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - Up to the duration of the ECT course (approximately several sessions over days)

Participants receive intermittent theta burst stimulation (iTBS) or sham TMS immediately before each electroconvulsive therapy (ECT) session as part of the treatment for treatment-resistant depression. The ECT dose is adjusted based on seizure threshold determined during the course.

Multiple visits corresponding to each ECT session with TMS priming

Follow-up

Duration - Within 2 days after completion of ECT course

Participants are monitored immediately after each ECT procedure and assessments are performed within 2 days after the course of ECT to evaluate recovery, cognitive function, and antidepressant response.

Approximately 1 to 2 visits post-treatment

Trial Site Locations

Total: 1 location

1

General University Hospital, Psychiatry department

Prague, Czech, Czechia, 120 39

Actively Recruiting

Loading map...

Research Team

D

Daniel Divacky

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

FACTORIAL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

A Pilot Phase II Trial of Add-on Oral Slow-Release Ketamine ...

Major Depressive Disorder (MDD)

Actively Recruiting

1 location

An Efficacy and Safety Study Comparing Two Doses of CYB003 a...

Major Depressive Disorder (MDD)

Actively Recruiting

67 locations

A Phase 2 Randomized, Double-blind, Placebo-controlled Trial...

Major Depressive Disorder (MDD)

Actively Recruiting

2 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here